alzamend.com - ALZN Full Business Value

Alzamend Neuro, Inc. (ALZN) is developing drugs for Alzheimer's disease, demonstrating complete independence from economic cycles and GDP. The business model relies on outsourcing production and trials, which minimizes capital expenditures. This price chart captures the enterprise value at -1.85. The current development vector is focused on implementing cellular methods and lithium formulas through the gradual completion of safety validation stages.

Enterprise value combines market capitalization and net debt to determine the actual cost of a full business buyout. By analyzing the aggregate asset valuation of Alzamend Neuro, Inc. (ALZN), an investor can see the real volume of capital currently being directed by Alzamend Neuro, Inc. (ALZN) toward molecule screening automation and the implementation of software robots for processing geriatric neurology data sets.